Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CardieX ( (AU:CDX) ) just unveiled an announcement.
Cardiex Limited has announced the closing of its Entitlement Offer, set for 5:00 pm AEST on 20 June 2025. This offer allows eligible shareholders to purchase new shares at $0.04 each, matching the price of a recent Institutional Placement. The initiative is part of Cardiex’s efforts to bolster its financial standing and support its mission to innovate in the field of vascular health. This move is expected to enhance shareholder value and strengthen the company’s market position.
More about CardieX
Cardiex is a company focused on advancing medical technology for vascular health, with products including medical and home health devices, as well as digital solutions for conditions like hypertension and cardiovascular disease. Their offerings are based on the SphygmoCor® vascular biomarker technology, and the company is listed on the Australian Stock Exchange under the ticker ASX: CDX.
Average Trading Volume: 300,084
Technical Sentiment Signal: Sell
Current Market Cap: A$21.45M
See more insights into CDX stock on TipRanks’ Stock Analysis page.